Abaloparatide and paclitaxel combination therapy Improves bone volume and tumor burden in Bone-Metastatic breast cancer
•Abaloparatide is FDA-approved for osteoporosis but is not well characterized in patients with bone metastases.•Combination abaloparatide and paclitaxel reduced tumor and increased bone volume in an intratibial model of cancer in bone.•Abaloparatide alone did not impact tumor burden or bone volume in tumor limb.
Authors
- Jade S. Miller (ORCID: https://orcid.org/0000-0001-6607-9602)
- Patricia Ward
- Julie A. Sterling (ORCID: https://orcid.org/0000-0002-7442-6085)
- Jeremy Kane
- Rachelle W. Johnson
- Marvel Shawkey
- Adaline Watkins
Institutions
- Sewanee: The University of the South (US)
- Vanderbilt University (US)
- VA Tennessee Valley Healthcare System (US)
- Belmont University (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- Journal of bone oncology
- Published
- 2026-02-21
- DOI
- https://doi.org/10.1016/j.jbo.2026.100752
- Primary Topic
- Bone health and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00